Infantile spasms followed by childhood absence epilepsy: A case series

Lucio Giordano1, Renato Tambucci2, Isabella Emanuela Cocco1

  • 1Child Neuropsychiatric Division, Spedali Civili, Brescia, Italy.

Seizure
|December 17, 2019
PubMed

Insights

Childhood absence epilepsy (CAE) may develop in infants with infantile spasms (IS) of unknown cause and favorable outcome. This study found that 29% of such children later developed CAE, suggesting a potential link.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Developmental Neuroscience

Background:

  • Infantile spasms (IS) are a severe epilepsy syndrome in infants.
  • IS are classified by etiology: known or unknown cause.
  • Unknown cause IS with favorable outcome (UC/FO) have a generally good prognosis.

Purpose of the Study:

  • To determine the prevalence of childhood absence epilepsy (CAE) in children with UC/FO IS.
  • To investigate the potential association between UC/FO IS and the subsequent development of CAE.

Main Methods:

  • Multicenter retrospective chart review across eight Italian pediatric epilepsy centers.
  • Identification of children diagnosed with UC/FO IS who later developed CAE.
  • Analysis of demographic, clinical, and treatment data.

Main Results:

  • 29% (7 out of 24) of children with UC/FO IS were subsequently diagnosed with CAE.
  • Mean age at IS onset was 5.8 months; seizure control was achieved by 8.5 months.
  • CAE was diagnosed around 8.0 years, with most patients responding well to valproic acid.

Conclusions:

  • A significant proportion of UC/FO IS patients developed CAE later in childhood.
  • This association suggests a possible underlying thalamo-cortical dysfunction.
  • Further research is needed to confirm causality.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
432
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
756
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
827